View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by Modality Solutions

Case Study: Immunomedics

Free White Paper

Case Study: Immunomedics

By Modality Solutions

Case Study: Immunomedics

By Modality Solutions
Enter your details to receive the free paper:

Immunomedics ( is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.

Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of Antibody-Drug Conjugates (ADC).

The US Food and Drug Administration (FDA) has granted fast-track designation for sacituzumab govitecan (IMMUNO-132).

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology